EHC reports Q1 2026 results today against a backdrop where options traders have rarely been this bullish — but the stock is coming off a rough 24 hours.
The clearest positioning signal heading into the print is in options. The put/call ratio collapsed to 0.11 on April 30, nearly three standard deviations below its 20-day average of 0.30 — the lowest reading of the past year. That is an extraordinary tilt toward calls. It suggests the options market is positioned for an upside surprise, not a hedge-driven defensive crouch.
The short side tells a quiet story that reinforces that read. Short interest in EHC has fallen more than 15% over the past month to roughly 3% of the free float — a level that is neither extreme nor particularly threatening. Borrow costs are low at 0.51% APR, and the lending pool is abundantly available, with availability running at multiples of current short interest. Bears have been retreating, not piling in. The ORTEX short score of 33.7 — comfortably in the lower half of the universe — reflects that picture.
Price action, though, is a mild complication. EHC closed at $100.00 on April 30, down 2.5% on the day and off 1.8% on the week, after a month that was marginally positive. That one-day slip lands the stock squarely at a round-number level that will draw attention if the print disappoints. Most correlated peer rallied 2.6% on the same day, and added 3.6% — divergence that highlights EHC's relative softness into the number.
The fundamental debate revolves around growth execution versus cost risk. The bull case rests on a multi-year revenue guide that has consistently moved higher, and a Medicare Advantage payer mix that has roughly doubled since 2018 to around 16.5% — a structural shift that broadens the reimbursement base. The bear case targets the company's de novo and joint-venture expansion pipeline, which carries real construction and staffing cost exposure in an environment where tariffs and competitive labor markets are both headwinds. The 2025 adjusted EBITDA target of $1.245 billion is the specific number bears argue may be squeezed. Analyst consensus, while stale since February, had been uniformly constructive — Barclays, UBS, and B of A Securities all carried Buy-equivalent ratings with targets well above the current price, with the mean sitting around $143. That gap of roughly 43% above spot reflects how far the stock has retreated from where the Street had been anchoring. T. Rowe Price added more than 1.5 million shares in Q1 2026, the largest institutional move among top holders — a signal that at least one active manager used the dip to build conviction.
Inside the company, the tone heading into results has been mixed. The CEO and CFO sold shares in late February at prices around $107–$108, now above the current close. Those were relatively modest in size, and the Treasurer's larger March sale of nearly 12,000 shares at $107 carries a significance score consistent with routine activity. Net insider flow over 90 days is nonetheless net positive in shares, even as cash proceeds were sizeable — a muted rather than alarming signal.
Today's print will test whether EHC's expansion program is tracking ahead of the cost pressures its bears have flagged — and whether a 43% gap to consensus analyst targets reflects a genuine discount or an anchor that needs resetting.
See the live data behind this article on ORTEX.
Open EHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
